secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0000929638-23-003305
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene appoints Ryan Daws as CFO and Head of Business Development; new CMO agreement with Richard Bryce
--------------------------------------------------------------------------------

- Ryan Daws appointed CFO and Head of Business Development, effective Nov 27, 2023; replaces Alexandre Grassin.
- Daws receives $440K base salary, 40% bonus, $143.5K signing bonus, and 232,000 stock options vesting over 4 years.
- CMO Richard Bryce enters employment agreement with $450K base, 40% bonus, eligibility for 153,000 stock options in 2024.
- Bryce's agreement provides severance: 12 months base salary plus benefits upon termination or change in control.
- enGene's lead program EG-70 in pivotal study for BCG-unresponsive NMIBC; interim data read-out expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/0000929638-23-003305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-23-003305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer